$2.37
+0.0000%PetMed Express, Inc., together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, and other pet supplies. It sells its products through its Internet website; mobile app; telephone contact center; and direct mail/print, which includes brochures and postcards, as well as television advertising under the 1-800-PetMeds and PetMeds brands. PetMed Express, Inc. was incorporated in 1996 and is headquartered in Delray Beach, Florida.
Chief Accounting Officer
Chief Digital & Technology Officer
Chief Financial Officer
Chief Marketing Officer
Chief Operating Officer
Corporate Controller & Corporate Secretary
President, Chief Executive Officer & Director
Compensation
$28,658
Vice President of People
During the last 12 months, insiders have purchased $955K worth of PETS shares, with no selling activity reported.
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
297.0K
954.91K
0
0.00
+955K
+$955K
Silvercape Investments Ltd
10 Percent Owner
$867K
Nina Capital Holdings Inc.
10 Percent Owner
$87K
No selling activity
Strong bullish signal with $955K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Perfect buy/sell ratio. Only buying activity with zero sellingโthe most bullish possible insider signal.
2 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
PETS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | December 10, 2025 | January 21, 2026 | 2026 | |
DEF 14A DEF 14A 2024 N/A | June 24, 2024 | August 08, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | June 20, 2023 | August 03, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | June 17, 2022 | July 28, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | June 17, 2021 | July 30, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | June 19, 2020 | July 31, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | June 14, 2019 | July 26, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | June 11, 2018 | July 27, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | June 12, 2017 | July 28, 2017 | 2017 | |
DEF 14A DEF 14A 2016 N/A | June 13, 2016 | July 29, 2016 | 2016 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.